QUOTED. 28 January 2021. Andrea Riposat.
L'Aquila, Italy-based Dante Laboratories company announced a £30m investment in global surveillance of new variants of the SARS-CoV-2 virus. CEO Andrea Riposat discussed the purchase.
“The SARS-CoV-2 RNA may be simpler to analyze than the human genome. Yet both require massive investments in software.” – Andrea Riposat, CEO, Dante Labs
Click here for a free trial of Medtech Insight